News and Trends 6 Dec 2017 CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […] December 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […] December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 4 Dec 2017 Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […] December 4, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 Belgian Firm Raises €80M for Rapid Infection and Cancer Tests Biocartis is aiming to raise funds through a private placement of shares in order to support sales and further development of its rapid cancer tests. Based in Mechelen, Belgium, Biocartis focuses on developing fast, easy-to-use diagnostics. In order to boost its molecular diagnostics technology, the company launched a private equity placement of shares on Euronext […] November 29, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 Merck and Pfizer’s Checkpoint Inhibitor Fails to Treat Gastric Cancer Avelumab, marketed as Bavencio by Pfizer and Merck, has failed to show better efficacy than chemotherapy in a Phase III trial with gastric cancer patients. Merck (the German one) and Pfizer joined the checkpoint inhibitor club earlier this year with the approval of Bavencio (avelumab) in both the US and Europe. Looking to keep expanding the […] November 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 Dutch Cancer Nanoparticles Get €2.5M from the EU to Enter Phase II The EU has awarded Cristal Therapeutics a grant from its Horizon 2020 program. This will support the development of its cancer nanoparticles through Phase II. Horizon 2020 is the biggest EU Research and Innovation program with close to €80B already handed out to help exciting science towards the market. Cristal Therapeutics is a biopharmaceutical company developing targeted nanomedicines for cancer and […] November 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 The EU Gives €6.3M Grant to Anti-Cancer Consortium The consortium of companies will use the EU’s money to support the development of personalized therapies for breast and rectal cancers. Horizon 2020 is the biggest ever EU Research and Innovation program with almost €80B made available to take exciting science to the market. The initiative has awarded a €6.3M grant to a group of companies brought […] November 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2017 Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells Scientists at Cardiff University have used CRISPR/Cas9 genome editing technology to produce highly specific killer T cell receptors. Researchers at Cardiff University have replaced the regular receptors found on T cells with their own, which are geared up to better tracking down and killing cancer cells. The research reported in Blood explained how the group removed receptors that interact with immune cells […] November 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 German Biotech Reels in €34M for its Cancer-Killing Technology Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […] November 21, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Cancer Sensor Raises the Alarm and Puts the Fire Out No need to call the fire brigade! The University of Dresden’s cancer sensor spots a mutation to p53, the most important cancer gene, and kills the cell. Researchers at the University of Dresden, Germany, have developed a molecular sensor that detects a mutation in tumor protein p53 – implicated in 50% of cancers – and kills […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 Anti-Parasite Drug May Help to Treat Prostate Cancer, Say Norwegian Scientists Researchers in Norway have found that a drug used to kill parasites like tapeworms can slow the growth of prostate and colon cancer cells. A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Nov 2017 Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […] November 16, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email